Sprint Bioscience AB (publ) announced that Erik Kinnman has been appointed as new CEO of the company. He has 25 years of experience from leading positions in the pharmaceutical and biotechnology industry. Erik Kinnman will take up the role on March 1 and succeed Charlotte Leife, who has been acting CEO since September 1, 2021. Erik Kinnman was between 2016 and January 2021 CEO of Abliva AB (formerly Neurovive). Prior to that, he held senior positions at AstraZeneca and SOBI and was also active as a financial analyst at Danske Bank.